Prolactin Secreting Pituitary Carcinoma and the Role of Peptide Receptor Radionuclide Therapy: A Brief Report.

IF 0.9 3区医学 Q4 NEUROSCIENCES

Neurology India Pub Date : 2024-07-01 Epub Date: 2024-08-31 DOI:10.4103/neurol-india.Neurol-India-D-24-00529

Nitish Agarwal, Satish Kumar Verma, Vikram Raj Gopinathan, Mehar Chand Sharma, Anima Sharma, Sarat P Chandra

{"title":"Prolactin Secreting Pituitary Carcinoma and the Role of Peptide Receptor Radionuclide Therapy: A Brief Report.","authors":"Nitish Agarwal, Satish Kumar Verma, Vikram Raj Gopinathan, Mehar Chand Sharma, Anima Sharma, Sarat P Chandra","doi":"10.4103/neurol-india.Neurol-India-D-24-00529","DOIUrl":null,"url":null,"abstract":"<p><p>Pituitary carcinoma is a rare entity comprising 0.1-0.2% of all pituitary tumors and presents significant diagnostic and therapeutic challenges. Intraspinal drop metastasis in these tumors is even rarer. We report a case of a prolactin secreting pituitary carcinoma with intracranial metastasis and multiple intraspinal drop metastasis. This is the first case where 68Gallium labelled [1,4,7,10 - tetraazacyclododecane - 1,4,7,10 - tetraacetic acid] -1- NaI3 - octreotide (68Ga-DOTANOC) whole-body positron emission tomography-computed tomography (PET-CT) has been used in a case of malignant prolactinoma, in an attempt to ascertain the somatostatin receptor (SSTR) expression on tumor cells. Through this paper, we suggest that SSTR targeted radionuclide therapy could have a potential role in aggressive pituitary tumors and pituitary carcinomas similar to the promising role of lutetium-labelled peptides in inoperable or metastasized gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).</p>","PeriodicalId":19429,"journal":{"name":"Neurology India","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology India","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/neurol-india.Neurol-India-D-24-00529","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/31 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Pituitary carcinoma is a rare entity comprising 0.1-0.2% of all pituitary tumors and presents significant diagnostic and therapeutic challenges. Intraspinal drop metastasis in these tumors is even rarer. We report a case of a prolactin secreting pituitary carcinoma with intracranial metastasis and multiple intraspinal drop metastasis. This is the first case where 68Gallium labelled [1,4,7,10 - tetraazacyclododecane - 1,4,7,10 - tetraacetic acid] -1- NaI3 - octreotide (68Ga-DOTANOC) whole-body positron emission tomography-computed tomography (PET-CT) has been used in a case of malignant prolactinoma, in an attempt to ascertain the somatostatin receptor (SSTR) expression on tumor cells. Through this paper, we suggest that SSTR targeted radionuclide therapy could have a potential role in aggressive pituitary tumors and pituitary carcinomas similar to the promising role of lutetium-labelled peptides in inoperable or metastasized gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).

查看原文本刊更多论文

分泌催乳素的垂体癌和肽受体放射性核素疗法的作用：简要报告。

脑垂体癌是一种罕见肿瘤，占所有脑垂体肿瘤的 0.1-0.2%，给诊断和治疗带来了巨大挑战。此类肿瘤的椎管内转移更为罕见。我们报告了一例泌乳素分泌型垂体癌伴有颅内转移和多发性椎管内坠积转移的病例。这是首次在恶性催乳素瘤病例中使用 68Gallium 标记的[1,4,7,10 - tetraazacyclododecane - 1,4,7,10 - tetraacetic acid] -1- NaI3 - octreotide（68Ga-DOTANOC）全身正电子发射断层扫描-计算机断层扫描（PET-CT），试图确定肿瘤细胞上体泌素受体（SSTR）的表达情况。通过本文，我们认为SSTR靶向放射性核素疗法在侵袭性垂体瘤和垂体癌中可能发挥潜在作用，就像镥标记肽在无法手术或转移的胃肠胰神经内分泌肿瘤（GEP-NETs）中发挥的作用一样。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurology India 医学-神经科学

CiteScore

1.60

自引率

70.40%

发文量

434

审稿时长

2 months

期刊介绍： Neurology India (ISSN 0028-3886) is Bi-monthly publication of Neurological Society of India. Neurology India, the show window of the progress of Neurological Sciences in India, has successfully completed 50 years of publication in the year 2002. ‘Neurology India’, along with the Neurological Society of India, has grown stronger with the passing of every year. The full articles of the journal are now available on internet with more than 20000 visitors in a month and the journal is indexed in MEDLINE and Index Medicus, Current Contents, Neuroscience Citation Index and EMBASE in addition to 10 other indexing avenues. This specialty journal reaches to about 2000 neurologists, neurosurgeons, neuro-psychiatrists, and others working in the fields of neurology.